New hope for rare bone disease: experimental drug aims to help patients walk better
NCT ID NCT06079281
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests an experimental drug called ALXN1850 in 124 adolescents and adults with hypophosphatasia, a rare genetic bone disease. Participants receive either the drug or a placebo by injection under the skin. The main goal is to see if the drug improves walking distance in 6 minutes, with other measures like sit-to-stand ability and pain. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALXN1850 (recombinant alkaline phosphatase)
What this could lead to
If successful, this could provide a new treatment option for hypophosphatasia, improving mobility and reducing pain for people who have not used other therapies.
What could go wrong
This is a phase 3 trial, but results are not yet available. The drug may not work better than placebo, and side effects from the injection or the drug itself are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Indianapolis, Indiana, 46202, United States
-
Research Site
Garden City, New York, 11530, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Columbus, Ohio, 43203, United States
-
Research Site
Nashville, Tennessee, 37212, United States
-
Research Site
Ciudad de Buenos Aires, C1199, Argentina
-
Research Site
Clayton, 3168, Australia
-
Research Site
Herston, 4029, Australia
-
Research Site
Parkville, 3052, Australia
-
Research Site
St Leonards, 2065, Australia
-
Research Site
Belo Horizonte, 30130-100, Brazil
-
Research Site
Brasília, 71625-009, Brazil
-
Research Site
Recife, 50740-465, Brazil
-
Research Site
Salvador, 40050-410, Brazil
-
Research Site
São Paulo, 01409-902, Brazil
-
Research Site
São Paulo, 05403-900, Brazil
-
Research Site
Calgary, Alberta, T2E 7H7, Canada
-
Research Site
Edmonton, Alberta, T6G 2R7, Canada
-
Research Site
Winnepeg, Manitoba, R3E 3P4, Canada
-
Research Site
Oakville, Ontario, L6M 1M1, Canada
-
Research Site
Trois-Rivières, Quebec, G9A 4P3, Canada
-
Research Site
Beijing, 100039, China
-
Research Site
Beijing, 100730, China
-
Research Site
Changsha, 430033, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 201306, China
-
Research Site
Shenzhen, 518053, China
-
Research Site
Paris, 75014, France
-
Research Site
Poitiers, 86000, France
-
Research Site
Bad Reichenhall, 83435, Germany
-
Research Site
Berlin, 10117, Germany
-
Research Site
Bonn, 53127, Germany
-
Research Site
Hamburg, 20251, Germany
-
Research Site
Würzburg, 97074, Germany
-
Research Site
Ashkelon, 7830604, Israel
-
Research Site
Ramat Gan, 52621, Israel
-
Research Site
Florence, 50139, Italy
-
Research Site
Milan, 20122, Italy
-
Research Site
Milan, 20132, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Pisa, 56126, Italy
-
Research Site
San Giovanni Rotondo, 71013, Italy
-
Research Site
Verona, 37134, Italy
-
Research Site
Hiroshima, 734-8551, Japan
-
Research Site
Iizuka-shi, 820-8505, Japan
-
Research Site
Osaka, 545-8586, Japan
-
Research Site
Sapporo, 060-8648, Japan
-
Research Site
Yaizu-shi, 425-8505, Japan
-
Research Site
Lodz, 93-338, Poland
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 07061, South Korea
-
Research Site
Suwon, 16499, South Korea
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Granada, 18016, Spain
-
Research Site
Madrid, 28046, Spain
-
Research Site
San Cristóbal de La Laguna, 38320, Spain
-
Research Site
Santander, 39008, Spain
-
Research Site
Vitoria-Gasteiz, 01009, Spain
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Yakutiye, 25040, Turkey (Türkiye)
-
Research Site
London, SW170QT, United Kingdom